Clinical differences between botulinum neurotoxin type A and B.

[1]  G. Duarte,et al.  Botulinum toxin type B for cervical dystonia. , 2016, The Cochrane database of systematic reviews.

[2]  Brian H. Raphael,et al.  Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). , 2015, Analytical chemistry.

[3]  N. Lowe,et al.  Botulinum Toxin Type B: pH Change Reduces Injection Pain, Retains Efficacy , 2014, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[4]  J. Jankovic,et al.  IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated , 2014, Journal of the Neurological Sciences.

[5]  J. Jankovic,et al.  Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. , 2014, Toxicon : official journal of the International Society on Toxinology.

[6]  Curtis N. James,et al.  Biologics: Targets and Therapy Dovepress Video Abstract Botulinum Toxin Type a Products Are Not Interchangeable: a Review of the Evidence , 2022 .

[7]  Eric A. Johnson.  Validity of botulinum neurotoxin serotype H. , 2014, The Journal of infectious diseases.

[8]  S. Arnon,et al.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. , 2014, The Journal of infectious diseases.

[9]  Gary Xie,et al.  Molecular characterization of a novel botulinum neurotoxin type H gene. , 2014, The Journal of infectious diseases.

[10]  M. Hallett,et al.  Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. , 2013, Toxicon : official journal of the International Society on Toxinology.

[11]  Alberto Esquenazi,et al.  Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. , 2013, Toxicon : official journal of the International Society on Toxinology.

[12]  D. Charles,et al.  Continuation of Long-Term Care for Cervical Dystonia at an Academic Movement Disorders Clinic , 2013, Toxins.

[13]  M. Hallett,et al.  Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. , 2013, Toxicon : official journal of the International Society on Toxinology.

[14]  J. Heinke,et al.  Originally published as , 2013 .

[15]  W. Prager,et al.  Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose‐conversion ratio for the treatment of glabellar frown lines , 2012, Journal of cosmetic dermatology.

[16]  K. Hoffmann,et al.  A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines , 2012, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[17]  M. Naumann,et al.  Immunogenicity of botulinum toxins , 2012, Journal of Neural Transmission.

[18]  M. Lew,et al.  Immunogenicity and Long-Term Efficacy of Botulinum Toxin Type B in the Treatment of Cervical Dystonia: Report of 4 Prospective, Multicenter Trials , 2012, Clinical neuropharmacology.

[19]  C. Shoemaker,et al.  Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex , 2012, Science.

[20]  A. Berardelli,et al.  Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review , 2012, Neurotoxicity Research.

[21]  J. Matsumoto,et al.  Clinical failure of botulinum toxin A in movement disorders. , 2012, Parkinsonism & related disorders.

[22]  A. Bentivoglio,et al.  Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story , 2012, Neurological Sciences.

[23]  J. Jankovic,et al.  Flu-like symptoms following botulinum toxin therapy. , 2011, Toxicon : official journal of the International Society on Toxinology.

[24]  A. Bentivoglio,et al.  Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double‐blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[25]  C. Windischberger,et al.  Long‐term efficacy and respective potencies of botulinum toxin A and B: a randomized, double‐blind study , 2011, The British journal of dermatology.

[26]  M. Brin,et al.  Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications , 2010, Movement disorders : official journal of the Movement Disorder Society.

[27]  M. Atassi.  Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action. , 2009, Toxicon : official journal of the International Society on Toxinology.

[28]  C. Montecucco,et al.  Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg , 2009, Muscle & nerve.

[29]  K. Wohlfarth,et al.  Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing? , 2009, Clinical neuropharmacology.

[30]  D. Dressler,et al.  Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity , 2009, Journal of Neural Transmission.

[31]  A. Bentivoglio,et al.  Outcome predictors, efficacy and safety of Botox and Dysport in the long‐term treatment of hemifacial spasm , 2009, European journal of neurology.

[32]  A. Bentivoglio,et al.  Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs , 2009, Neurotoxicity Research.

[33]  T. Hunt,et al.  Potency Evaluation of a Formulated Drug Product Containing 150-kd Botulinum Neurotoxin Type A , 2008, Clinical neuropharmacology.

[34]  J. Jankovic,et al.  Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay , 2008, Movement disorders : official journal of the Movement Disorder Society.

[35]  E. Pappert,et al.  Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trial , 2008, Movement disorders : official journal of the Movement Disorder Society.

[36]  C. Adler,et al.  Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open‐label, dose‐escalation safety study , 2007, Movement Disorders.

[37]  A. Bentivoglio,et al.  Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. , 2007, Parkinsonism & related disorders.

[38]  J. Jankovic,et al.  Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia , 2006, Neurology.

[39]  J. Wissel,et al.  Using translational medicine to understand clinical differences between botulinum toxin formulations , 2006, European journal of neurology.

[40]  V. P. Misra,et al.  Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram‐guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test , 2006, Movement disorders : official journal of the Movement Disorder Society.

[41]  B. Voller,et al.  Pain Sensation during Intradermal Injections of Three Different Botulinum Toxin Preparations in Different Doses and Dilutions , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[42]  L. Provinciali,et al.  Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[43]  W. Jost,et al.  Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm , 2006, Journal of Neural Transmission.

[44]  M. Barnes,et al.  The use of botulinum toxin type‐B in the treatment of patients who have become unresponsive to botulinum toxin type‐A – initial experiences , 2005, European journal of neurology.

[45]  A. Blitzer.  Botulinum Toxin A and B: A Comparative Dosing Study for Spasmodic Dysphonia , 2005, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[46]  J. Jankovic,et al.  Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia , 2005, Neurology.

[47]  J. Jankovic,et al.  Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial , 2005, Neurology.

[48]  S. Factor,et al.  Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[49]  E. Růžička,et al.  A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia , 2005, Neurology.

[50]  L. Baumann,et al.  Pilot study of the safety and efficacy of Myobloc™ (botulinum toxin type B) for treatment of axillary hyperhidrosis , 2005, International journal of dermatology.

[51]  L. Baumann,et al.  Double‐Blind, Randomized, Placebo‐Controlled Pilot Study of the Safety and Efficacy of Myobloc (Botulinum Toxin Type B) for the Treatment of Palmar Hyperhidrosis , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[52]  L. Seeberger,et al.  Long‐term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[53]  J. Leuchs.  Beiträge zur Kenntnis des Toxins und Antitoxins des Bacillus botulinus , 1910, Zeitschrift für Hygiene und Infektionskrankheiten.

[54]  E. Ermengem.  Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus , 1897, Zeitschrift für Hygiene und Infektionskrankheiten.

[55]  D. Dressler,et al.  Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. , 2005, Journal of neurology.

[56]  C. Sampaio,et al.  Botulinum toxin type B for cervical dystonia. , 2005, The Cochrane database of systematic reviews.

[57]  J. Jankovic,et al.  Botulinum toxin in clinical practice , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[58]  A. Brashear,et al.  Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. , 2004, Archives of physical medicine and rehabilitation.

[59]  D. Dressler.  Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy , 2004, Movement disorders : official journal of the Movement Disorder Society.

[60]  M Zouhair Atassi,et al.  Basic immunological aspects of botulinum toxin therapy , 2004, Movement disorders : official journal of the Movement Disorder Society.

[61]  Roberto Eleopra,et al.  Different types of botulinum toxin in humans , 2004, Movement disorders : official journal of the Movement Disorder Society.

[62]  W. Ondo,et al.  A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease , 2004, Neurology.

[63]  P. Roggenkämper,et al.  Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.

[64]  J. Callaway.  Botulinum toxin type B (Myobloc®): pharmacology and biochemistry , 2004 .

[65]  J. Callaway.  Botulinum toxin type B (Myobloc): pharmacology and biochemistry. , 2004, Clinics in dermatology.

[66]  J. Jankovic,et al.  Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia , 2003, Neurology.

[67]  N. Sadick.  Botulinum Toxin Type B , 2003, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[68]  G. Petzold,et al.  Botulinum toxin type B in blepharospasm and hemifacial spasm , 2003 .

[69]  D. Dressler,et al.  Autonomic Side Effects of Botulinum Toxin Type B Treatment of Cervical Dystonia and Hyperhidrosis , 2002, European Neurology.

[70]  O. Suchowersky,et al.  Long‐term efficacy of botulinum toxin A in treatment of various movement disorders over a 10‐year period , 2002, Movement disorders : official journal of the Movement Disorder Society.

[71]  J. Jankovic,et al.  CROSS REACTION OF TETANUS AND BOTULINUM NEUROTOXINS A AND B AND THE BOOSTING EFFECT OF BOTULINUM NEUROTOXINS A AND B ON A PRIMARY ANTI-TETANUS ANTIBODY RESPONSE , 2002, Immunological investigations.

[72]  A. Brashear.  Botulinum toxin type B: a new injectable treatment for cervical dystonia , 2001, Expert opinion on investigational drugs.

[73]  G. Dirnberger,et al.  Botulinum Toxin Antibody Testing: Comparison between the Immunoprecipitation Assay and the Mouse Diaphragm Assay , 2001, European Neurology.

[74]  M. Brin,et al.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. , 1999, Neurology.

[75]  J. Jankovic,et al.  Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies , 1999, Journal of neurology, neurosurgery, and psychiatry.

[76]  R. Benecke,et al.  Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency , 1999, Journal of Neurology.

[77]  J. Dolly,et al.  Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Jankovic,et al.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. , 1999, Neurology.

[79]  R. Benecke,et al.  Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. , 1999, Journal of neurology.

[80]  Joseph Jankovic,et al.  Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response , 1998, Neurology.

[81]  J. Palace,et al.  A radioimmunoprecipitation assay for antibodies to botulinum A , 1998, Neurology.

[82]  R. Burke,et al.  Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. , 1998, Brain : a journal of neurology.

[83]  C. Sampaio,et al.  DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1 , 1997, Movement disorders : official journal of the Movement Disorder Society.

[84]  C. O’Brien,et al.  BotB (botulinum Toxin type B): Evaluation of safety and tolerability in botulinum toxin type A‐Resistant cervical dystonia patients (preliminary study) , 1997, Movement disorders : official journal of the Movement Disorder Society.

[85]  K. Wohlfarth,et al.  Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences , 1997, Experimental Neurology.

[86]  J. Jankovic,et al.  Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia , 1997, Neurology.

[87]  R. Sloop,et al.  Human response to botulinum toxin injection: Type B compared with type A , 1997, Neurology.

[88]  R. Benecke,et al.  The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A , 1997 .

[89]  R. Benecke,et al.  The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A. , 1997, Movement disorders : official journal of the Movement Disorder Society.

[90]  M. Goodnough,et al.  Botulinum toxin therapy, immunologic resistance, and problems with available materials , 1996, Neurology.

[91]  M. Schulzer,et al.  Botulinum toxin type B in the treatment of cervical dystonia , 1995, Neurology.

[92]  K. Schwartz,et al.  Response and immunoresistance to botulinum toxin injections , 1995, Neurology.

[93]  S Fahn,et al.  Development of resistance to botulinum toxin type A in patients with torticollis , 2004, Movement disorders : official journal of the Movement Disorder Society.

[94]  C. Hatheway,et al.  Immunogenicity of the neurotoxins of Clostridium botulinum , 1994 .

[95]  Mark Hallett,et al.  Therapy with botulinum toxin , 1994 .

[96]  N. Bathien,et al.  Botulinum antibodies in dystonic patients treated with type A botulinum toxin , 1993, Neurology.

[97]  J. Jankovic,et al.  Therapeutic uses of botulinum toxin. , 1991, The New England journal of medicine.

[98]  D. Gelb,et al.  Change in pattern of muscle activity following botulinum toxin injections for torticollis , 1991, Annals of neurology.

[99]  J. Elston,et al.  Botulinum toxin therapy for squint , 1988, Eye.

[100]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[101]  D. Musch,et al.  Treatment of blepharospasm with botulinum toxin. A preliminary report. , 1984, Archives of ophthalmology.

[102]  Scott Ab.  Botulinum toxin injection of eye muscles to correct strabismus. , 1981 .

[103]  A. B. Scott,et al.  Botulinum toxin injection of eye muscles to correct strabismus. , 1981, Transactions of the American Ophthalmological Society.

[104]  A. B. Scott,et al.  Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. , 1980, Journal of pediatric ophthalmology and strabismus.

[105]  E. V. Ermengem.  A New Anaerobic Bacillus and Its Relation to Botulism , 1979 .

[106]  E. van Ermengem.  Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897. , 1979, Reviews of infectious diseases.

[107]  G. S. Burke.  The Occurrence of Bacillus botulinus in Nature. , 1919, Journal of bacteriology.